Anthony Petrone
Stock Analyst at Mizuho
(4.12)
# 521
Out of 5,124 analysts
210
Total ratings
54.55%
Success rate
11.74%
Average return
Main Sectors:
Stocks Rated by Anthony Petrone
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNDM Tandem Diabetes Care | Maintains: Neutral | $18 → $21 | $21.98 | -4.46% | 2 | Dec 17, 2025 | |
| MDXG MiMedx Group | Maintains: Outperform | $12 → $10 | $6.77 | +47.71% | 5 | Dec 17, 2025 | |
| LIVN LivaNova | Maintains: Outperform | $70 → $72 | $61.53 | +17.03% | 10 | Dec 17, 2025 | |
| LNTH Lantheus Holdings | Maintains: Outperform | $60 → $72 | $66.55 | +8.19% | 7 | Dec 17, 2025 | |
| INSP Inspire Medical Systems | Maintains: Outperform | $110 → $130 | $92.23 | +40.95% | 7 | Dec 17, 2025 | |
| HAE Haemonetics | Maintains: Outperform | $75 → $90 | $80.15 | +12.29% | 16 | Dec 17, 2025 | |
| GH Guardant Health | Maintains: Outperform | $100 → $120 | $102.14 | +17.49% | 4 | Dec 17, 2025 | |
| ESTA Establishment Labs Holdings | Maintains: Outperform | $85 → $90 | $72.80 | +23.63% | 9 | Dec 17, 2025 | |
| DXCM DexCom | Maintains: Outperform | $75 → $78 | $66.37 | +17.52% | 3 | Dec 17, 2025 | |
| COO The Cooper Companies | Maintains: Outperform | $85 → $100 | $81.96 | +22.01% | 16 | Dec 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $32.73 | +22.21% | 1 | Dec 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $110 → $100 | $78.81 | +26.89% | 11 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $310 → $300 | $240.87 | +24.55% | 18 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 → $100 | $85.25 | +17.30% | 10 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $70 → $78 | $74.49 | +4.71% | 10 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $130 → $135 | $122.04 | +10.62% | 9 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $140 → $135 | $125.29 | +7.75% | 6 | Jul 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $17 → $18 | $23.09 | -22.04% | 8 | Jul 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $98 → $100 | $96.06 | +4.10% | 7 | Jul 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $12 | $11.88 | +1.01% | 3 | Jul 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $200 → $175 | $112.91 | +54.99% | 10 | Apr 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $5.52 | +624.64% | 1 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $60 | $101.56 | -40.92% | 1 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $54 → $58 | $81.88 | -29.16% | 2 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $100 → $110 | $95.35 | +15.36% | 8 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $14 | $18.24 | -23.25% | 6 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $110 → $105 | $82.02 | +28.02% | 6 | May 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $350 → $390 | $566.36 | -31.14% | 6 | Jan 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $63 → $67 | $81.10 | -17.39% | 2 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $175 | $89.92 | +94.62% | 3 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $30 → $25 | $11.65 | +114.59% | 3 | May 13, 2020 |
Tandem Diabetes Care
Dec 17, 2025
Maintains: Neutral
Price Target: $18 → $21
Current: $21.98
Upside: -4.46%
MiMedx Group
Dec 17, 2025
Maintains: Outperform
Price Target: $12 → $10
Current: $6.77
Upside: +47.71%
LivaNova
Dec 17, 2025
Maintains: Outperform
Price Target: $70 → $72
Current: $61.53
Upside: +17.03%
Lantheus Holdings
Dec 17, 2025
Maintains: Outperform
Price Target: $60 → $72
Current: $66.55
Upside: +8.19%
Inspire Medical Systems
Dec 17, 2025
Maintains: Outperform
Price Target: $110 → $130
Current: $92.23
Upside: +40.95%
Haemonetics
Dec 17, 2025
Maintains: Outperform
Price Target: $75 → $90
Current: $80.15
Upside: +12.29%
Guardant Health
Dec 17, 2025
Maintains: Outperform
Price Target: $100 → $120
Current: $102.14
Upside: +17.49%
Establishment Labs Holdings
Dec 17, 2025
Maintains: Outperform
Price Target: $85 → $90
Current: $72.80
Upside: +23.63%
DexCom
Dec 17, 2025
Maintains: Outperform
Price Target: $75 → $78
Current: $66.37
Upside: +17.52%
The Cooper Companies
Dec 5, 2025
Maintains: Outperform
Price Target: $85 → $100
Current: $81.96
Upside: +22.01%
Dec 1, 2025
Initiates: Outperform
Price Target: $40
Current: $32.73
Upside: +22.21%
Nov 11, 2025
Maintains: Outperform
Price Target: $110 → $100
Current: $78.81
Upside: +26.89%
Oct 31, 2025
Maintains: Outperform
Price Target: $310 → $300
Current: $240.87
Upside: +24.55%
Oct 31, 2025
Maintains: Outperform
Price Target: $90 → $100
Current: $85.25
Upside: +17.30%
Oct 23, 2025
Downgrades: Neutral
Price Target: $70 → $78
Current: $74.49
Upside: +4.71%
Aug 1, 2025
Maintains: Neutral
Price Target: $130 → $135
Current: $122.04
Upside: +10.62%
Jul 18, 2025
Maintains: Neutral
Price Target: $140 → $135
Current: $125.29
Upside: +7.75%
Jul 16, 2025
Maintains: Neutral
Price Target: $17 → $18
Current: $23.09
Upside: -22.04%
Jul 16, 2025
Maintains: Outperform
Price Target: $98 → $100
Current: $96.06
Upside: +4.10%
Jul 16, 2025
Maintains: Neutral
Price Target: $13 → $12
Current: $11.88
Upside: +1.01%
Apr 16, 2025
Maintains: Outperform
Price Target: $200 → $175
Current: $112.91
Upside: +54.99%
Apr 10, 2025
Initiates: Outperform
Price Target: $40
Current: $5.52
Upside: +624.64%
Apr 10, 2025
Initiates: Outperform
Price Target: $60
Current: $101.56
Upside: -40.92%
Mar 6, 2025
Maintains: Buy
Price Target: $54 → $58
Current: $81.88
Upside: -29.16%
Oct 24, 2024
Maintains: Outperform
Price Target: $100 → $110
Current: $95.35
Upside: +15.36%
Jun 20, 2024
Maintains: Buy
Price Target: $12 → $14
Current: $18.24
Upside: -23.25%
May 1, 2024
Maintains: Buy
Price Target: $110 → $105
Current: $82.02
Upside: +28.02%
Jan 25, 2024
Maintains: Neutral
Price Target: $350 → $390
Current: $566.36
Upside: -31.14%
Aug 3, 2023
Downgrades: Hold
Price Target: $63 → $67
Current: $81.10
Upside: -17.39%
Nov 5, 2021
Maintains: Buy
Price Target: $200 → $175
Current: $89.92
Upside: +94.62%
May 13, 2020
Maintains: Hold
Price Target: $30 → $25
Current: $11.65
Upside: +114.59%